Johnson & Johnson's Executive Leadership: The Architects Behind the Kenvue Separation and Innovative Medicine Growth
核心洞察
Joaquin Duato, CEO since 2022 and Chairman since 2023, oversaw the landmark separation of J&J's consumer health segment into the independent publicly traded company Kenvue (搜索).
Jennifer Taubert, Worldwide Chairman of Innovative Medicine, previously doubled the pharmaceuticals business in the Americas, making J&J the number one pharma company in the U.S. and Canada.
CFO Joseph Wolk played a key role in executing the consumer health business separation, bringing extensive financial leadership across both Innovative Medicine and MedTech divisions.
Johnson & Johnson's executive leadership team continues to shape the strategic direction of one of the world's largest healthcare corporations, with a renewed focus on Innovative Medicine and MedTech following the historic separation of its consumer health division. The leadership roster, led by Chairman and CEO Joaquin Duato, reflects decades of internal experience and a deliberate pivot toward high-growth pharmaceutical and medical technology markets.
Leadership at the Helm
Joaquin Duato, who joined Johnson & Johnson in 1989 at Janssen Pharmaceuticals (搜索) in Spain, ascended to the role of Chief Executive Officer in January 2022 and assumed the additional title of Chairman in January 2023. His career trajectory at the company spans more than three decades, during which he served as Vice Chairman of the Executive Committee, leading the company's pharmaceutical and consumer health businesses while overseeing supply-chain and technology operations.
Duato's most consequential strategic move to date has been overseeing the separation of Johnson & Johnson's consumer health segment, which now operates as an independent publicly traded company under the name Kenvue (搜索). His healthcare roots run deep: his mother was a nurse, his grandfather a pediatrician, and his grandmother a pharmacist. Duato holds an MBA from ESADE Business School in Barcelona and a Master of International Management from Thunderbird School of Global Management. He previously served as Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) from 2017 to 2018 and has held board positions with UNICEF USA and Tsinghua University School of Pharmaceutical Sciences.
Financial Stewardship
Joseph J. Wolk, who joined Johnson & Johnson in 1998, has served as Executive Vice President and Chief Financial Officer since 2018. His tenure includes senior financial leadership roles across the enterprise: Vice President of Investor Relations, Vice President of Finance for J&J Innovative Medicine, Vice President of Finance for J&J MedTech's Global Supply Chain, and CFO of the North America Innovative Medicine Group. Wolk played a key role in executing the consumer health business separation. He holds a BS in Finance from St. Joseph's University and a JD from Temple University School of Law, and is also a Certified Public Accountant. Notably, Wolk represents a multi-generational connection to the company — his father, uncle, and aunt also worked at Johnson & Johnson.
Innovative Medicine Leadership
Jennifer L. Taubert serves as Executive Vice President and Worldwide Chairman of Innovative Medicine, having joined Johnson & Johnson in 2005 after 18 years at Merck (搜索) and Allergan. At J&J, she led global commercial strategy for the pharmaceuticals business and, as President of Internal Medicine, built a new franchise in cardiovascular and metabolic disease (搜索). Under her leadership as Company Group Chairman for The Americas, the pharmaceuticals business doubled in size, becoming the number one pharmaceutical company in the United States and Canada. Taubert holds a Bachelor's degree in Pharmacology from UC Santa Barbara and an MBA from UCLA's Anderson Graduate School of Management. She has served on the Board of Directors of McDonald's Corporation since 2022.
MedTech and Corporate Affairs
Tim Schmid, Executive Vice President and Worldwide Chairman of MedTech, leads an organization of over 75,000 employees generating approximately $30 billion in revenue, focused on developing and delivering innovative medical technologies.
Vanessa Broadhurst, Executive Vice President of Global Corporate Affairs, rounds out the executive committee, leading strategies across Corporate Marketing, Global Communications, Global Health Equity, and Worldwide Government Affairs & Policy.
The collective leadership team reflects Johnson & Johnson's post-Kenvue (搜索) identity — a pure-play healthcare company concentrated on pharmaceutical innovation and medical technology, guided by executives with deep institutional knowledge and cross-functional expertise.